Product Information
GABAPENTIN ER 300 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.6385 per EA under NDC 31722009190. Its NADAC has been published 116 times since Jul 17, 2024.
FDA first approved this application on Feb 26, 2024. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the GABAPENTIN market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722009190
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA218075FDA Approved
2/26/2024
TE Code
AB2
On Market Since
2/26/2024
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN ER 300 MG TABLET has been published 116 times since Jul 17, 2024, and over the history we have for it it has declined 61.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6385 per EA |
|---|---|
| All-time high | $2.2901 (Jun 11, 2025) |
| All-time low | $0.6385 (Sep 23, 2026) |
| 52-week high | $1.8909 |
| 52-week low | $0.6385 |
| Median price | $1.5247 |
| Average price | $1.6202 |
| Largest weekly change | +35.5% (Aug 21, 2024) |
| Weeks tracked | 116 |
| Tracking since | Jul 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the GABAPENTIN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
GABAPENTIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN ER 300 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.6385 per EA (NDC 31722009190), effective Sep 30, 2026.
How has the price of GABAPENTIN ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for GABAPENTIN ER 300 MG TABLET has declined 61.1%. It has been tracked across 116 weekly CMS publications since Jul 17, 2024.
What are the highest and lowest recorded NADAC prices for GABAPENTIN ER 300 MG TABLET?
Since Jul 17, 2024, the NADAC for GABAPENTIN ER 300 MG TABLET has ranged from a low of $0.6385 (Sep 23, 2026) to a high of $2.2901 (Jun 11, 2025), with a median of $1.5247 per EA.
Are there cheaper alternatives to GABAPENTIN ER 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of GABAPENTIN ER 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GABAPENTIN ER 300 MG TABLET?
GABAPENTIN ER 300 MG TABLET (NDC 31722009190) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.